Solvay Reports Higher Sales and Profit; Focuses on 'Optimal Reinvestment' Following Disposal of Pharma Unit

Solvay's recurring group operating result (Rebit) from continuing operations, following the sale of its pharmaceuticals business, rose to €183 million ($237.8 million) in the second quarter of this year, compared to €63 million in the same period of 2009. Sales were down 11% to €1.85 billion, following the divestment of the pharma business but up 32% compared with chemicals and plastics in the first quarter of 2009. Chemicals sales were 12% higher at €762 million while plastics revenues rose 50% to €1.1 billion. Second quarter chemicals...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers